AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage

AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver. The final LCD becomes effective July 5, 2026.

The final LCD advances a reimbursement infrastructure already underway. Effective January 1, 2026, the American Medical Association CPT® Editorial Panel activated Category I CPT codes for IRE procedures in the prostate and liver, representing the AMA's formal recognition that a procedure is clinically effective, reflects widespread physician adoption, and carries established clinical value. Category I codes include physician Relative Value Units (RVUs) and support standardized billing across hospital outpatient departments and ambulatory surgical center settings. The Palmetto GBA LCD provides the corresponding coverage framework, enabling eligible patients and treating physicians to access reimbursement for IRE procedures under Medicare and marking an important step toward broader national payer adoption.